Investigating platelet transfusion thresholds for extremely preterm infants
2/2 Neonatal Platelet Transfusion Threshold Trial (NeoPlaTT)
['FUNDING_OTHER'] · RESEARCH TRIANGLE INSTITUTE · NIH-11088186
This study is looking at very premature babies born between 23 to 26 weeks to find out the best amount of platelets to give them to help prevent serious bleeding and improve their chances of survival during their first week in the NICU.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RESEARCH TRIANGLE INSTITUTE (nih funded) |
| Locations | 1 site (RESEARCH TRIANGLE PARK, UNITED STATES) |
| Trial ID | NIH-11088186 on ClinicalTrials.gov |
What this research studies
This research focuses on extremely preterm infants born between 23 to 26 weeks of gestation, who are at high risk for bleeding and thrombocytopenia. The study aims to determine the optimal platelet transfusion threshold to minimize the risk of severe bleeding and mortality in these vulnerable infants. By comparing lower and higher transfusion thresholds, the research seeks to provide evidence-based guidelines for platelet transfusions in the Neonatal Intensive Care Unit (NICU). The approach involves a multicenter trial that will enroll infants during their critical first week of life, where the risk of complications is highest.
Who could benefit from this research
Good fit: Ideal candidates for this research are extremely preterm infants born at 23 to 26 weeks of gestation who are admitted to the NICU.
Not a fit: Patients who are not extremely preterm or those who are older than 28 weeks of gestation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and reduced bleeding complications in extremely preterm infants.
How similar studies have performed: Previous studies, such as the PlaNeT-2 trial, have shown promising results with lower platelet transfusion thresholds in similar populations, indicating potential for success in this research.
Where this research is happening
RESEARCH TRIANGLE PARK, UNITED STATES
- RESEARCH TRIANGLE INSTITUTE — RESEARCH TRIANGLE PARK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DAS, ABHIK — RESEARCH TRIANGLE INSTITUTE
- Study coordinator: DAS, ABHIK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.